Reusing Reclaimed Precast Concrete Elements in New Buildings – Tampere University, Finland, Coordinates a Major International Project
Concrete is widely used as a construction material, but it has a substantial environmental impact. When a building is demolished, what happens to all the concrete? Tampere University, Finland, is coordinating the new international ReCreate project, which aims to discover how used concrete elements can be deconstructed without damaging them and reused in new buildings – and to turn the process into a profitable business. The four-year project has received €12.5 million of funding under the EU’s Horizon 2020 programme.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005850/en/
When a building is demolished, what happens to all the concrete? Tampere University, Finland, is coordinating the new international ReCreate project, which aims to discover how used concrete elements can be deconstructed without damaging them and reused in new buildings – and to turn the process into a profitable business. Photo by Tampere University.
Concrete has been the world’s most commonly used building material for at least half a century. It accounts for the majority of both construction materials and demolition waste. In Europe, concrete buildings are commonly constructed using precast concrete elements. If the old elements could be reused instead of manufacturing new ones, it would bring major benefits for the environment.
“By reusing concrete elements, we can save an enormous amount of energy and raw materials,” says Satu Huuhka, adjunct professor at the Faculty of Built Environment at Tampere University, who leads the ReCreate project.
The recently launched international ReCreate project (2021–2025) coordinated by Tampere University seeks to find new uses for the concrete elements of condemned buildings in the construction of new buildings. The four-year project has received funding under the European Union’s Horizon 2020 call, and it seeks solutions for reusing construction and demolition waste. The project has an overall budget of €12.5 million. The project involves universities and regional company clusters in four countries: Finland, Sweden, the Netherlands, and Germany. The communications partner is the Croatia Green Building Council. All the country clusters will carry out their own pilot projects where they deconstruct precast concrete elements intact and reuse them in a new building.
“We are specifically looking to reuse the concrete elements as a whole, not as a raw material for something new,” Huuhka points out.
Tapping into Finland’s world-class expertise
Researchers at the Faculty of Built Environment have been carrying out ground-breaking research into the circular economy in the construction sector for a decade. In addition, long-term research on renovation and the lifecycle engineering of structures provides a solid foundation for the development of quality assurance procedures that will ensure the safety and integrity of the reused elements. This time, the researchers are set to explore not only the technical implementation of the solutions but also the business perspective.
“There are many questions to be answered. How do we deconstruct the elements from buildings without damaging them? How do we assess their structural integrity? How do we recertify the salvaged elements and turn them into a product that meets building code requirements? Since the elements are not of uniform quality, how can we turn this into a viable business? We must also consider the social aspects: does the process require new skills or new ways of working?” Huuhka asks.
Tampere University researchers will also bring to the project their specialist expertise in circular economy business models, building regulations and law, and occupational sociology. The Finnish country cluster comprises Tampere University, the construction company Skanska, the demolition company Umacon, the precast concrete company Consolis Parma, the engineering and consultancy company Ramboll, the architecture firm Liike Oy Arkkitehtistudio and the City of Tampere.
The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees.www.tuni.fi/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Project manager Tommi Halonen
Sustainable Tampere 2030 programme, City of Tampere
tel. +358 44 481 1007
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma22.6.2021 16:31:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe. The second authorisation is for the use of daratumumab SC in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have
PPG Introduces Digital Color-Matching Device for Commercial Vehicles22.6.2021 15:02:00 CEST | Press release
PPG (NYSE: PPG) today announced the introduction of its ColorReader portable digital device, which will enable customers in the commercial vehicle sector to quickly and precisely match colors to the PPG DELFLEET ONE® color palette and international standard colors. ColorReader is a BLUETOOTH®-connected device that works with a dedicated app. Available for iOS and Android tablets and smartphones, the device provides a highly accurate color match in just a few seconds. “All users have to do is download the ColorReader app, connect with their smartphone or tablet, and place ColorReader on the painted surface to scan,” said Jo Thompson, PPG color marketing manager, automotive refinish, Europe, Middle East and Africa. “ColorReader also offers a smart solution when a smartphone or tablet is not available by instantly displaying the three closest matching colors on its built-in display after scanning.” PPG recently launched ColorReader in Europe, the Middle East and Africa, and has received a
Personalis Announces NeXT Level Biomarkers Symposium22.6.2021 15:01:00 CEST | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium, which will showcase novel research into emerging biomarkers using the Personalis NeXT Platform™. This event will detail the latest research from Personalis as well as a case study done in collaboration with the Parker Institute for Cancer Immunotherapy. Presentations from Personalis will focus on recently published research into HLA loss of heterozygosity, neoantigen prediction, as well as Personalis’ novel composite biomarker, the Neoantigen Presentation Score (NEOPS™). In addition, Dr. Theresa LaVallee will be presenting findings from the PRINCE trial based on data developed and analyzed in collaboration with Personalis. The agenda for NeXT Level Biomarkers Symposium will cover: Biomarker Discovery with ImmunoID NeXT Platform® Exploring HLA LOH with the DASH (Deletion of Allele-Specific HLAs) Algorithm Neoantigen Binding Prediction and Bioma
Kymeta Joins the U.S. Army’s Armored Brigade Combat Team Pilot Program22.6.2021 15:00:00 CEST | Press release
Kymeta (www.kymetacorp.com), the communications company making mobile global, announced today that it has been selected to participate in the U.S. Army’s Armored Brigade Combat Team (ABCT) satellite communications on the move (SOTM) pilot program. The program will assess communications solutions on select vehicles to enhance battlefield network and command post communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005288/en/ The Kymeta u8 is the comprehensive connectivity solution that is available today and enables trusted, secure communications on the go and on the pause with a host of innovative features. (Photo: Business Wire) The ABCT pilot program will be led by General Dynamics Mission Systems, and Kymeta will supply eight u8 terminals for integration and testing on a variety of ABCT vehicles. Kymeta is the world’s first and only metamaterial-based SOTM terminal, and its electronically steered flat pane
Anna Biosciences Launches Pioneering Immunotherapeutic Treatment to Fight COVID-1922.6.2021 15:00:00 CEST | Press release
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem. The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease. Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem P
National Arena Bucharest Completes Fast-Paced Addition of LED Stadium Lighting for UEFA EURO 202022.6.2021 15:00:00 CEST | Press release
In preparation to host UEFA EURO 2020, National Arena Bucharest has been fitted with a state-of-the-art LED lighting system – a project that was designed, shipped, and installed in just two months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005161/en/ National Arena Bucharest Completes Fast-Paced Addition of LED Stadium Lighting for UEFA EURO 2020 (Photo: Business Wire) The new LED lighting was installed to augment the stadium’s existing metal halide lights, in order to meet television broadcast standards set for by UEFA for the global event. The new lighting was designed and engineered by Musco, utilizing its Total Light Control—TLC for LED™ system. “We are now sure that we will have a spectacular EURO,” said Florin Sari, Leader Local Organizing Structure EURO 2020 Bucharest. “The win will be a stadium that will be able to host any kind of top competition from now on also.” Equally impressive as the new system’s t
Mavenir and MobiledgeX Enable Global Edge Connectivity With Deutsche Telekom22.6.2021 15:00:00 CEST | Press release
Mavenir, in collaboration with MobiledgeX and Deutsche Telekom, have demonstrated and validated the reference design for deploying cloud-native 5G User Plane Function (UPF) to support Multi-Access Edge Computing (MEC) applications, tailored to each use case need for proximity and performance. The reference design is fully cloud-native, abstracted away from underlying cloud architecture, infrastructure vendor and operating owner. “We are excited to partner with Mavenir and MobiledgeX to demonstrate dynamic cloud-native deployment of 5G Core UPF for users where it is needed. The UPF can run inside the operator’s owned network, inside a private 4G/5G network, inside the roaming network, or in the public cloud. The ability to dynamically and seamlessly orchestrate traffic across our own footprint and the footprint of others opens up the possibility for new connectivity solutions for customers,” says Alex Choi, SVP Strategy & Technology Innovation, Deutsche Telekom. A service-based, cloud-n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom